Patents Assigned to The Research Foundation for Microbial Diseases
-
Patent number: 8507443Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.Type: GrantFiled: August 19, 2005Date of Patent: August 13, 2013Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto
-
Patent number: 8492532Abstract: A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus contain(s) nucleotide mutations that produce one or more amino acid mutations that attenuate the virus.Type: GrantFiled: November 20, 2008Date of Patent: July 23, 2013Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kouichi Morita, Takeshi Nabeshima, Shinichi Miyake, Toshiyuki Onishi, Isao Fuke, Toyokazu Ishikawa, Hideo Goda, Masahide Ishibashi, Michiaki Takahashi
-
Publication number: 20130101620Abstract: A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Applicant: The Research Foundation For Microbial Diseases of Osaka UniversityInventor: The Research Foundation For Microbial Diseases
-
Publication number: 20120220028Abstract: Disclosed is an enhancer for a viral promoter such as a promoter that can induce expression selectively and strongly in immunocompetent cells (e.g., lymphocytes) or blood cells. It is found unexpectedly that an intron has the above-mentioned enhancer activity. Thus, it is found that an enhancer for a promoter, which comprises an intron sequence for a major immediate early gene (MIE) of human herpes virus-6 (HHV-6) (particularly HHV-6B) or a fragment of the intron sequence, has a potent promoter activity.Type: ApplicationFiled: September 3, 2010Publication date: August 30, 2012Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITYInventors: Masaaki Matsuura, Masaya Takemoto, Tetsuo Koshizuka, Koichi Yamanishi, Yasuko Mori
-
Publication number: 20120058124Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.Type: ApplicationFiled: August 4, 2011Publication date: March 8, 2012Applicants: The Research Foundation for Microbial Diseases of Osaka University, FUJITA HEALTH UNIVERSITYInventors: Yoshikazu KUROSAWA, Yoshitaka IBA, Nobuko OHSHIMA, Yoshinobu OKUNO
-
Publication number: 20110230418Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.Type: ApplicationFiled: August 19, 2005Publication date: September 22, 2011Applicant: The Research Foundation For Microbial Diseases Of Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto
-
Patent number: 8013139Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: GrantFiled: August 21, 2008Date of Patent: September 6, 2011Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 8008467Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: GrantFiled: September 5, 2006Date of Patent: August 30, 2011Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 7887819Abstract: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasmodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.Type: GrantFiled: November 13, 2008Date of Patent: February 15, 2011Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventor: Toshihiro Horii
-
Patent number: 7820436Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: GrantFiled: May 8, 2009Date of Patent: October 26, 2010Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michlaki Takahashi, Koichi Yamanishi
-
Publication number: 20100247559Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.Type: ApplicationFiled: November 7, 2008Publication date: September 30, 2010Applicants: Japan as Represented by the Director-General of National Institute of Infectious Diseases, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Asato Kojima, Hidehiro Takahashi, Toyokazu Ishikawa
-
Patent number: 7749734Abstract: A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus contain(s) nucleotide mutations that produce one or more amino acid mutations that attenuate the virus.Type: GrantFiled: December 22, 2005Date of Patent: July 6, 2010Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Morita Kouichi, Takeshi Nabeshima, Shinichi Miyake, Toshiyuki Onishi, Isao Fuke, Toyokazu Ishikawa, Hideo Goda, Masahide Ishibashi, Michiaki Takahashi
-
Patent number: 7700546Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.Type: GrantFiled: June 20, 2006Date of Patent: April 20, 2010Assignee: The Research foundation for Microbial Diseases of Osaka c/o Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto
-
Publication number: 20100047247Abstract: The invention provides agents that promote or inhibit neurite elongation comprising as an active ingredient an antibody that recognizes a varicella-zoster virus immediate-early protein and cross-reacts with a brain-derived neurotrophic factor. The invention also provides methods of utilizing such agents to prevent or treat a nervous disease or a disease with nerve hypersensitivity caused by a condition selected from the group consisting of postherpetic neuralgia, chronic pains, experience-dependent social aversion and stress.Type: ApplicationFiled: November 16, 2007Publication date: February 25, 2010Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITYInventors: Kimiyasu Shiraki, Yuka Hama, Yoshihiro Yoshida, Masaaki Tsuda, Tadaharu Tsumoto, Shunro Endo, Michiaki Takahashi
-
Publication number: 20100005536Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: ApplicationFiled: September 5, 2006Publication date: January 7, 2010Applicant: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 7462358Abstract: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.Type: GrantFiled: September 8, 2006Date of Patent: December 9, 2008Assignee: The Research Foundation for Microbial Diseases of OsakaInventor: Toshihiro Horii
-
Publication number: 20070219149Abstract: The present invention provides an adjuvant that possesses a greater adjuvant potential than that of a conventional adjuvant, and that is capable of producing a protective reaction across different strains. This problem has been solved by the finding that a double-stranded RNA (for example, Poly(I:C)) unexpectedly exhibits the above capability when used in combination with a subunit antigen. Accordingly, the present invention provides a vaccine for mucosal administration containing A) a double-stranded RNA and B) a subunit antigen or inactivated antigen of a pathogen.Type: ApplicationFiled: August 10, 2004Publication date: September 20, 2007Applicants: The Research Foundation for Microbial Diseases of Osaka University, Japan as Represented by the Director-General of National Institute of Infectious Diseases, Toray Industries, Inc.Inventors: Hideki Hasegawa, Takeshi Kurata, Tetsutarou Sata, Masami Moriyama, Shin-ichi Tamura, Takeshi Tanimoto
-
Patent number: 6841374Abstract: The present invention provides a novel inactivated virus particle and a reinforced immunogen which have a reinforced titer about twice to about 10 times that of a conventional vaccine, as well as a method for producing the same. The inactivated virus particle is produced by inactivating and then purifying a culture by physical means. The inactivated virus particle of the present invention is useful in a diagnostic agent for infectious disease caused by a group of Japanese encephalitis virus.Type: GrantFiled: June 2, 1999Date of Patent: January 11, 2005Assignee: Research Foundation for Microbial Diseases of Osaka UniversityInventors: Toyokazu Ishikawa, Hironori Yoshii, Toshiyuki Onishi, Tadashi Imagawa, Masahide Ishibashi
-
Patent number: 6653069Abstract: Disclosed is a method for quality control of an attenuated varicella live vaccine, which comprises subjecting the genomic DNA of a sample varicella vaccine virus to sequence analysis and confirming that the genomic DNA of the sample varicella vaccine virus conserves the 5,745th G, the 105,356th C, the 105,544th G, the 106,262nd C and the 107,252nd C without suffering mutation, wherein the nucleotide numbers are in accordance with the nucleotide numbering system of the nucleotide sequence of the genomic DNA of the varicella virus Dumas strain of SEQ ID NO: 1.Type: GrantFiled: August 15, 2001Date of Patent: November 25, 2003Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yasuyuki Gomi, Hiroki Sunamachi, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 6605284Abstract: Disclosed is a measles virus mutant gene coding for a measles virus mutant H protein antigen, wherein said gene coding for a measles virus mutant H protein antigen is at least one member selected from the group consisting of the following genes (a) to (c): (a) a gene coding for an amino acid sequence of SEQ ID NO: 10; (b) a gene coding for an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 11; and (c) a gene coding for an amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 12. By the use of the measles virus mutant gene of the present invention, it has become possible to provide efficiently and economically a gene vaccine which is adapted for an epidemic strain of measles virus, and a diagnostic reagent capable of accurately detecting infections with an epidemic strain of measles virus.Type: GrantFiled: June 5, 2001Date of Patent: August 12, 2003Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Shigeharu Ueda, Michiko Watanabe, Hitomi Kawanish